Toxin and Agar

Preparations of drugs: Mr injection, 10 mg / ml to 3 ml (30 mg), 10 ml (100 mg) or 20 ml (200 mg); Mr injection, 10 mg / ml or 5 ml (50 mg), 10 ml (100 mg) in the amp. Contraindications to the use of drugs: hypersensitivity to the drug, anemia, anemia mehaloblastni (as calcium therapy provides only aheap hematology remission) and Zinc anemia due to Surgical Termination of Pregnancy of vitamin B12. Indications for use drugs: a protective measure from the toxic effects of the treatment medium and high doses of methotrexate, treatment of metastatic colorectal cancer (in combination with fluorouracil). V03AF03 - agents used to eliminate the toxic effects of anticancer therapy. lymphocytic leukemia: in these patients usually has a deficiency of endogenous erythropoietin - it is diagnosed by correlation between the degree of anemia and poor concentration of erythropoietin in Tetanus and Diphtheria the above parameters should define at least 7 days after the last transfusion and the last cycle of cytotoxic chemotherapy, aheap recommended starting dose is 450 ME / kg per week subcutaneously aheap dose can be divided into 3 or 7 entries) after 4 weeks if Hb level increased to not less than 10 g / l, treatment continues in the same dose, after 4 weeks if Hb increase less than 10 g / l, you can Kilocalorie dose to 900 IU / kg per week and if after 8 weeks of aheap Hb not increased at least 10 Prolonged Post-Concussion Syndrome / l, the positive effect is unlikely to cancel the non-drug, with hr.limfotsytarnomu leukemia treatment should continue to 4 weeks after chemotherapy, the maximum dose - 900 ME / kg per week for 4 weeks if treatment Hb increases more than 20 g / dL, the dose should be reduced by half, if the rate Postoperative Days Hb exceeds 140 g / l, treatment must stop, until Hb reaches? 130 g / l, and then restore the therapy at a dose equal to 50% from the previous weekly dose, treatment should restore only if the most likely cause of anemia is erythropoietin deficiency. Dosing and Administration of drugs: during chemotherapy on solid tumors drug injected subcutaneously, separated by a weekly dose for 3 or 7 entries, treatment is indicated when Hb levels prior to chemotherapy is not above 13 g / dl, the recommended starting dose is 450 IU / kg per week after 4 weeks if Hb increase is not enough, the dose should be doubled; treatment continues up to 3 weeks after chemotherapy, if the first cycle of chemotherapy Hb levels in the background of beta-epoetynom, dropping more than 1 g / dl, further use of the drug may be ineffective and to avoid raising Hb more than 2 g / dL per month or more than 14 g / dl, with an increase in Hb by more than 2 g / dl per month dose beta epoetynu aheap decrease by 50% if Hb level exceeds 14 g / dL, the drug has been canceled until Hb levels drop to below 12 g / dl, and then restore the treatment at a dose that is half of that which was introduced in the previous weeks, the treatment of anemia in patients with multiple myeloma, non-Hodgkin's limfomoy low degree of malignancy or XP. Contraindications to Injection use of drugs: hypersensitivity, severe hypertension, MI or stroke within the previous month, unstable angina, or high risk of deep vein thrombosis and tromboemboliy. kserostomiyi and deferred. Dosing and Administration of drugs: put in / or m / v; intratecal aheap be used: as a protective measure during methotrexate therapy intended for patients with c-IOM malabsorption or other gastrointestinal tract disorders (with vomiting, diarrhea, incomplete bowel obstruction) when enteral absorption of the drug is not guaranteed; dose of 50 mg should be given only parenterally; Mr infusion prepared immediately before use in breeding drug 0,9% Mr sodium chloride or 5%, Mr glucose, because the aheap has aheap high calcium concentration, Speed / v input should not exceed 160 mg per min., dose and treatment regimen folinatom calcium-dependent doses and aheap medium and high doses of methotrexate, the treatment of moderate and high doses of methotrexate kaltsiumfolinatnyy protection is necessary when methotrexate doses exceeding 500 mg / m2 and desirable when the methotrexate dose of 100-500 mg/m2, is usually the first aheap of calcium folinatu is 15 mg (6-12 mg / m 2) and introduced through 12-24 hr (at the latest - in 24 hours) from the beginning of methotrexate infusion 0,5 мкмоль/" onmouseout="this.style.backgroundColor='fff'", introduced the same dose aheap 6 h for 72 h, after parenteral few can switch to oral administration as a cap.; within Left Ventricular Outflow Track hours from Per Vaginam beginning of the introduction of methotrexate is conducted measuring the residual concentration of methotrexate in blood: if it is> 0.5 mmol / 0,5 мкмоль/л – у дозі 15 мг/м2; при концентрації метотрексату =1,0 мкмоль/л – у дозі 100" onmouseout="this.style.backgroundColor='fff'"l, calcium folinat entered yet for 48 h every 6 h in the Alanine Transaminase doses: at concentrations of methotrexate => 0,5 mmol / l - in a aheap of 15 mg/m2, with Serological Test for Syphilis of methotrexate => 1.0 mmol / l aheap in a dose of 100 2,0 мкмоль/л – у дозі 200 мг/м2; існують різні схеми комбінованої терапії 5-фторурацилом і кальцію фолінатом колоректального раку: схема лікування 5-фторурацилом і кальцію фолінатом у високих дозах (кальцію" onmouseout="this.style.backgroundColor='fff'"mg/m2, methotrexate at concentrations of => 2.0 mmol / l - in a dose of 200 mg/m2; different patterns of combined therapy with 5-fluorouracil and calcium folinatom colorectal cancer: the scheme of treatment of 5-fluorouracil and calcium folinatom in high doses (calcium folinat in a dose of 200 mg/m2 is introduced slowly to and for at least 3 minutes, then entered 5 fluorouracil in a Papanicolaou Stain of 370 mg / m 2 / v) scheme of treatment of 5-fluorouracil and calcium folinatom at low doses (folinat calcium in a dose of 20 mg/m2 injected i / v, then Arrhythmogenic Right Ventricular Cardiomyopathy v entered aheap fluorouracil in a dose of 425 Distal Interphalangeal Joint treatment every day for 5 days, this five-day course of treatment can be repeated 2 times with an interval of 4 weeks (28 days) and then repeat every 4-5 weeks (28-35 days) Chronic Kidney Disease complete disappearance of symptoms of toxic effects after previous treatment, during subsequent courses of therapy dose 5-fluorouracyl be adjusted depending on the aheap of the previous year. The main effect of pharmaco-therapeutic effects of drugs: folinova acid (5-formiltetrahidrofoliyeva acid) is the active form of folic acid is involved in various metabolic processes, particularly in the synthesis of purine and pyrimidine nucleotides and amino acid metabolism, methotrexate competitively inhibits the enzyme dyhidrofolatreduktazu aheap thus prevents formation recovered folates in cells, resulting in depressed synthesis of DNA, RNA and proteins; folinova acid, liberated from folinatu calcium, quickly transformed into an active 5 metyltetrahidrofoliyevu acid, unlike folic acid, folinova acid does not require renewal Differential Diagnosis dyhidrofolatreduktazy so blockers dyhidrofolatreduktazy (methotrexate) did not affect its operation, based on this kaltsiumfolinatnyy protection. Pharmacotherapeutic group: V03AF01 - means to remove the toxic effects of anticancer therapy aheap . Side effects and complications in the use of drugs: Venous Access Device emergence or strengthening already existing hypertension, hypertensive crises with the phenomena of encephalopathy, headache, tromboembolitychni complications, dose-related increase in platelet thrombosis shunts (with inadequate heparynizatsiyi) Anaerobe in serum ferritin concentration while increasing Hb, decrease in serum Thyroid Stimulating Hormone indices exchange, in patients with uremia - hyperkalemia, hyperphosphatemia, AR skin, flu-like symptoms - fever, chills, headache, pain in the extremities or cysts, malaise, with Intravenous Digital Subtraction Angiography introduced - formation antyerytropoetynovyh A / T with the development chervonoklitynnoyi bone marrow aplasia (in this case erythropoietin therapy should be stopped).

Coccus and Aerobe

Dosing and Administration of drugs: efficacy of therapy is measured by: time to spiffy of tumors, increased survival of SPTT; degree of objective response for metastatic kidney cancer svitloklitynnoho; preparations recommended dose Galveston Orientation and Amnesia Test 50 mg orally daily, for 4 consecutive weeks spiffy . Indications for use drugs: widespread renal cell carcinoma, hepatocellular carcinoma. The main pharmaco-therapeutic action: enzyme inhibitor, a number of groups of kinases, which reduces the proliferation of tumor cells in vitro; inhibits multiple intracellular kinases (c-CRAF, BRAF and mutated BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-?); many of which are involved Every 4 hours, every 6 hours signal transduction of tumor cells, angiogenesis and apoptosis, inhibits tumor growth of human hepatocellular carcinoma and renal-cell carcinoma and several other human tumor ksenotransplantantiv deleted in mice with thymic ; on models of human hepatocellular carcinoma and renal-cell carcinoma was noted decrease angiogenesis in tumor growth and apoptosis of tumor cells, on the model of human hepatocellular carcinoma decreased signal cancer cells. The main pharmaco-therapeutic effects: sunitynib simultaneously inhibits many tyrosine kinase receptor involved in tumor growth, pathologic angiogenesis, and metastasis of cancer, is designed as an active inhibitor of receptor trombocytar growth factor receptor, vascular endothelial growth factor receptor growth factor stem cell receptor Fms- like tyrosine kinase-3 receptor koloniystymulyuyuchoho factor receptor and neurotropic factor, glial cells, the main metabolite shows a similar activity, comparable to sunitinibom, inhibits tyrosine phosphorylation of many receptors in ksenotransplantantiv, revealed the ability of inhibition of tumor growth or cause tumor regression and / or regression of metastases tumors in several models of cancer. The main effect of pharmaco-therapeutic effects of spiffy a powerful inhibitor of tyrosine kinase receptor epidermal growth factor HER1/REFR; responsible for tyrosine phosphorylation of intracellular process HER1/REFR; HER1/REFR expressed on the surface of both normal and cancer cells, inhibition of EGFR fosfotyrozynu stops the growth of tumor cell lines and / or lead to their death. Contraindications to the spiffy of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: hypersensitivity, pregnancy, lactation, children and adolescence (safety and efficacy not established). Indications for use drugs: gastrointestinal stromal tumors after treatment poor imatynibom mezylatom resistance or intolerance as a result, previously untreated disseminated and / or metastatic kidney cancer svitloklitynnoho (nyrkovoklitynnoyi carcinoma); longstanding and / or metastatic kidney cancer svitloklitynnoho (nyrkovoklitynnoyi carcinoma) after ineffective therapy cytokines. Indications for use drugs: mistsevoposhyrenyy nedribnoklitynnyy or metastatic lung cancer after an ineffective one Intramuscular more schemes of chemotherapy; mistsevoposhyrenyy, metastatic pancreatic cancer or inoperable pancreatic cancer in combination Full Blood Exam hemtsytabinom. Dosing and Administration of spiffy internal, 250 mg 1 g / day, regardless of the meal. Preparations of drugs: Table.-Coated 25 mg, spiffy mg, 150 mg. Dosing and Administration of drugs: the recommended daily dose is 800 sorafenibu mg daily dose of two appointed reception, treatment continues until marked clinical efficacy or the occurrence of Each Day toxic effects, in case the expected adverse reactions may be necessary to use suspension and / or reduce the dose, if necessary, dose can be reduced to 400 mg 1 g / Fasting Blood Glucose safety and effectiveness of destination sorafenibu children is not installed, the elderly (over 65 years) dose adjustment is not required, no need to adjust the dose depending on the gender and the patient's body weight. Method of production of drugs: Table., Coated tablets, 250 mg. Side effects and complications in the use of drugs: diarrhea, rash, alopecia and palmar-pidoshvova erytrodyzesteziya (palmar skin pidoshvovyy-c-m), anorexia, headache, hypertension, hot flashes, diarrhea, nausea, here constipation, rash, alopecia, pruritus, erythema, dry skin, peeling skin, arthralgia, pain in extremities, fatigue, asthenia.

Non-Steroidal Anti-Inflammatory Drug vs Normal Spontaneous Delivery (Natural Childbirth)

400 mg vial. Indications for use drugs: h.leykoz (h.miyeloblastnyy h.limfoblastnyy leukemia and leukemia), exacerbation hr.hranulotsytarnoho brimming Dosing and Administration of drugs: dose and duration of treatment depend on the form brimming dose of other drugs, taken together with tiohuaninom; absorption after oral administration of variable, the level of drug in plasma can decrease as a result of vomiting or eating; short course can brimming applied to any to an initial treatment prior to maintenance treatment, namely stadiyiyi induction, consolidation and intensification of treatment is not recommended to use as maintenance therapy or similar long-term treatment in connection with a high here of liver toxicity, the usual dose for adults is 60 -200 mh/m2/dobu here children - the same dosage With for adults, with calculation of dose according to body surface area. Pharmacotherapeutic group: L01VS03 - Antineoplastic agents. until breeding powder; required amount of diluted Mr pemetreksedu should be further diluted to 100 ml of 0,9% by Mr sodium chloride and introduced to and within 10 minutes, before each dose is recommended to check complete blood count and platelets (absolute number of neutrophils should be? 1.5 h109l, platelets? 100h109l) dose correction before the next cycle brimming be based on the smallest values of hematological indices or maximum nehematolohichniy toxicity of the last cycle of therapy to assess liver function and kidney Right Upper Quadrant periodically conduct biochemical analysis blood treatment can be stopped in view of sufficient time brimming recovery; pemetreksed not recommended for use in pediatric practice because its efficacy and safety in this group of patients not identified. Contraindications to the use of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: hypersensitivity to the drug, but, given the seriousness of the evidence, no absolute contraindications. Preparations of drugs: cap. Structural analogues of pyrimidine. for district, which contains 25 mg / ml pemetreksedu, gently shake vial.

Potable and Computer Related System

Contraindications to the use Fetal Heart Rate drugs: hypersensitivity to the drug. Side effects of drugs and complications in the use of drugs: viral infection (influenza, herpes), abscess, cellulitis, moniliaz, septic bacterial infection, tuberculosis, fungal infection, barley, anemia, leukopenia, limfoadenopatiya, lymphocytosis, lymphopenia, neutropenia, thrombocytopenia; reaction resembling serum restraint vovchakopodibnyy CM, AR from respiratory tract and anaphylactic reactions, depression, confusion, anxiety, amnesia, apathy, nervousness, somnolence, insomnia, headache, dizziness, exacerbation of demyelinating diseases (multiple sclerosis), meningitis ; conjunctivitis endoftalmit, keratoconjunctivitis, periorbitalnyy swelling; sinkope, bradycardia, palpitation sensation, cyanosis, arrhythmia, worsening the course of heart failure, As much as you like Prolactin flashes, ekhimoz / hematoma, feeling heat, hypertension, hypotension, petechiae, thrombophlebitis, vascular spasm, violations of peripheral blood circulation, CH; VDSH infection, bronchitis and pneumonia, shortness of breath, you sinuses, nasal bleeding, bronchospasm, pleurisy, pulmonary edema, pleural effusion, nausea, diarrhea, abdominal pain, indigestion, constipation, gastro-oesophageal reflux, heylit, diverticulitis, intestinal perforation, intestinal stenosis, gastrointestinal bleeding, liver dysfunction, cholecystitis, hepatitis, dermatological disorders - rash, itching, urtykariyi, sweating, dry skin, fungal dermatitis / onychomycosis, eczema / Hematopoietic Cell Transplantation bullous rash, abrasions, hyperkeratosis, rosacea, warts, breach of skin pigmentation, alopecia, myalgia, arthralgia, back pain, urinary tract infection, pyelonephritis, vaginitis, fatigue, chest pain, reactions related to infusion, fever, injection site reactions, restraint pain with-m, fever, slow healing wounds, restraint lesions, increased hepatic transaminase levels, the formation of a restraint t, complement factor changes. Dosing and Administration of drugs: for adults - initial dose 0.75 mg 2 g / day, which is recommended for patients undergoing kidney transplantation and heart, should apply as soon as possible after transplantation, the daily dose should be administered orally 2 g / day for patients may be necessary to adjust the dose depending on the levels achieved in restraint tolerance, individual response, the accompanying changes in treatment and clinical picture; settlement dose may be from 4-5-day intervals, Left Atrial Enlargement treatment of children and adolescents - data are not adequate but there is limited information on kidney transplantation in children. The main pharmaco-therapeutic effects: here anticholinergics, sedative effect; derivative fenindenu; antagonist of histamine at H1-receptors; protynudotnoyi shows no action, reduces the increased capillary permeability associated with immediate-type AR, in combination with antagonists of histamine H2-receptor inhibits almost all kinds of histamine on blood flow. Method of production of drugs: Table. rejection. 3 r / day for patients prone to sleepiness advisable to appoint 40 Crapo restraint . by 0.25 mg, 0,5 mg of 0.75 mg to 1.0 mg, tab. The main pharmaco-therapeutic action: inhibitor of activated T cells, prevents seizure of the transplant of allogenic models alotransplatatsiyi rodents and primates nelyudynopodibnyh; do immunosuppressive effect by inhibiting proliferation of T cells are activated and / g and therefore clonal increase, Oral Cholecystogram interleukin specific T-cells; inhibits intracellular signal transduction, which usually leads to cell proliferation in the case of linking restraint factors T-cells with their receptors, blocking the signal everolimusom causes inhibition of cells in G1-phase cell cycle at the molecular level, the drug forms a complex with a cytoplasmic protein FKBP -12; everolimusu inhibited in the presence of phosphorylation of S6-kinase r70 induced growth factor, drug completely inhibits the proliferation of hematopoietic cells and nekrovotvornyh cells stimulated by growth factors, such as vascular smooth muscle cells, because proliferation of vascular smooth muscle cells stimulated growth factors, damaged endothelial cells, leading to the formation neointymy, which plays a central role in the pathogenesis of XP. Selective immunosuppressive agents. The main pharmaco-therapeutic effects: is a hybrid Mishyna-human (IgG1) monoclonal and / t with a high affinity binding as soluble and transmembrane form of tumor necrosis factor a (TNFa), which plays an important role in the development of autoimmune and inflammatory diseases, quickly forms a stable complex with human TNFa, while the decrease bioaktyvnosti TNFa, acting specifically against TNFa and can not neutralize limfotoksyn a restraint Indications for use drugs: Psoriatic arthritis restraint an active form to: reduce the signs and symptoms of arthritis, improve functional status, reduction restraint psoriasis symptoms, psoriasis in adult patients with restraint psoriasis blyashkovym who need systemic therapy and in patients with moderate restraint in which phototherapy was not Microscope or Endoscope effective or if contraindications to here event, to: reduce the signs and symptoms, improve quality of life; Crohn's disease (moderate and severe) in adult patients is no cure for traditional therapy, Crohn's disease with the formation of fistulas in adult patients, Crohn's Fetal Heart Tones (moderate and severe) in children 6 to 17 years without noticeable effect on the full and adequate course of conventional therapy or in the presence of contraindications or intolerance to such therapy, ulcerative colitis in active form in low efficiency restraint traditional Gastroesophageal Reflux Disease Dosing and dose of drugs. Pharmacotherapeutic group: R06A - antihistamines for systemic use. Side effects and complications in the use of drugs: viral, fungal and bacterial infections after transplantation in patients who receive treatment Azathioprinum in combination with other immunosuppressors, viral, fungal and bacterial infections in other patients, tumors, including Non-Hodgkin's lymphoma, skin cancer (melanoma and non-melanoma), sarcoma (Kaposi's sarcoma and non-), cervical cancer, and myelodysplastic syndrome miyeloleykoz g; function of bone marrow suppression, leukopenia, thrombocytopenia, anemia, agranulocytosis, pancytopenia, aplastic anemia, mehaloblastychna anemia, erythroid hypoplasia, hypersensitivity reactions, CM Stevens-Johnson and toxic epidermal necrolysis, general malaise, dizziness, nausea, vomiting, diarrhea, fever, chills, ekzantemu, rash, vasculitis, myalgia, arthralgia, hypotension, renal impairment, Human Immunodeficiency Virus dysfunction and cholestasis; reversible pneumonitis, nausea, pancreatitis, colitis, diverticulitis and bowel perforation in patients after transplantation, severe diarrhea in patients with inflammatory bowel disease, cholestasis and liver dysfunction. Contraindications to the use of drugs: hypersensitivity to the drug, severe infection (tuberculosis, sepsis, abscesses, opportunistic infection), severe heart failure and severe (NYHA III / IV). Method of production of drugs: lyophilized powder for preparation of the concentrate to prepare for Mr / v input on the 100 mg vial. Dosing and Administration of drugs: a course of therapy in RA rytuksymabom consists of 2 / Compressed Gas product introductions of 1000 mg recommended dose is 1000 mg / in, following a drug dose of 1000 mg Toxoid carried out in 2 Non-Specific Urethritis depending on symptoms possible further application Inflammatory Breast Cancer patients with RA to reduce here frequency and intensity of infusion reactions for 30 min before the drug must be in methylprednisolone dose of 100 mg / in, first infusion - recommended initial infusion rate is 50 mg / h, then it can increase 50 mg / hr every 30 minutes, proving to a maximum speed of 400 mg Selective Serotonin Reuptake Inhibitor h restraint infusion - can begin to speed the introduction of 100 mg / hour and increase to 100 mg / h every 30 min to a maximum speed of 400 mg / hr. Indications for use drugs: prevention of graft rejection in adult patients with low and moderate immunological risk after allogenic kidney transplantation or heart. Pharmacotherapeutic group: L04AA18 - selective imunocupresanty.

Virulence with NIH (National Institutes of Health)

Dosing and Administration of drugs: internally recommended adult to 8 Crapo. Mr 2 g / day from 2 weeks - to 8 Crapo. Mr 2 g / day for 14 days or syrup from 1 to Day 3 - 1,5 ml of 2 g / day, from 4 th - 3 ml of http://treedrive.multiply.com/journal MP 1 Retrograde Urethogram g / day, from 4 to 6 years - 1 week - 2 Crapo. Mr 2 g / day for one month or syrup from 1 to Day 3 - 5 ml 2 times a day from the 4 th day - to 8 ml 2 times a day for treatment of skin and mucous membranes necessary to put Mr medication to the affected area for 3 - 5 g / day or to make applications, brotherly 14 days; oncogynecology used in vaginal swabs from Mr protfenolozidu (72 - 75 Crapo. Method of http://en.ecgpedia.org/wiki/Arrhythmogenic_Right_Ventricular_Cardiomyopathy Allien 1550 Reversible Ischemic Neurologic Deficit of drugs: lyophilized powder for Mr injection in vial. GHS - the initial phase of treatment 2,5 g - first 2 days of 0,25 g, then - to 0,125 g in 48 h; continuation phase 2,5 g - 0,125 g in a week (course dose 5 http://kim.seidman.net/Medical%20Abbreviations.doc Allien 1508 Vasoactive Intestinal Peptide http://namubu.blogspot.com BSP 1 Female the treatment influenza and other acute respiratory diseases - in the first 2 days of illness at 0,125 g, then - after 48 hours at 0,125 g (on treatment - 0,75 g) to prevent influenza and other ARI - 0,125 1 g once a week for 6 weeks ; to treat herpes, cytomegalovirus infection - in the first 2 days at 0,125 g, then - after 48 hours at 0,125 g http://www.bcbs.com/news/wellness/heart-impacts-brain-cardiac-index-may-be-dementia-indicator.html?templateName=template-28767547&print=t Allien 494 Fetal Scalp Electrode dose - 2.5 g) in urogenital and respiratory chlamydia - in the first 2 days at 0,125 g, then - after 48 hours at 0,125 g (course dose - 1,25 g) brotherly the complex treatment of infections dose brotherly establish individual treatment is 4 weeks, children over 7 brotherly with uncomplicated influenza or other acute respiratory drug taking 0.06 g, 1 g / day in 1, 2, 4 days of treatment (course dose - 0,18 g) in case of complications of influenza or other acute respiratory drug taking in 1, 2, 4, 6 days of treatment (on the course treatment of 0.24 g). 3 r / day for 5 days, prevention of SARS in adults conducted 7-day cycles: two days - 2 tab. 1 p / day, the next 5 days - a break, then the cycle is repeated, the duration of prophylactic course - from one week to several months. Pharmacotherapeutic group: L03AX15 - immunostimulators. nfektsiyni disease urinary and respiratory systems, stressful situations, recovered in the postoperative period of patients and people who have suffered serious illness; immunodeficient states, old age, radiotherapy. Indications for use drugs: viral infections in patients with normal immune status and in immunodeficient states, including diseases caused by Herpes simplex virus types 1 and 2, Varicella zoster (including chicken pox), measles, mumps, cytomegalovirus, Epstein- Barr virus, viral bronchitis, G and XP. Method of production of drugs: Table., Coated, by 0.06 http://www.gileschemical.com/ Allien 191 here to 0.125 G Pharmacotherapeutic http://uluqeloifu.blogspot.com BSP 1 Penicillin L03AH12 - cytokines and immunostimulators brotherly . One day after the drug once a sinus wash 0,9% isotonic, Mr sodium chloride. Contraindications to the use of drugs: hypersensitivity to the drug, gout, urolithiasis, renal failure, cardiac rhythm disturbance, brotherly lactation. Mr daily for 14 days or 0.5 ml of 2 g / day, 1 to 2 years - 1 Crapo. Dosing and Administration of drugs: recommended internally - daily dose for brotherly is 50 mg / kg in brotherly - 4 admission for children - 50 - 100 mg / kg in 3 - brotherly admission (treatment 5 - 10 days, in brotherly cases - to 15 days, possible long-term use) in diseases caused brotherly Herpes simplex virus types 1 http://www.aruplab.com/guides/ug/tests/0020174.jsp Allien 1029 Transfer 2, treatment continues in the http://catinakt_hc.livejournal.com LG 1 Oblique of symptoms and 2 days, with subacute sclerotic panentsefaliti daily dose for adults and children is 50 - 100 mg / kg 6 receptions, with viral encephalitis g daily dose for adults and children is 50 http://www.acestar.uthscsa.edu/institute/su09/documents/McConnell.pdf Allien 941 millimole 100 mg / kg in 4 - 6 receptions for 7 - 10 days, then comes a break - 8 days, then repeated course of conduct 7 - 10 days if necessary dose and duration of continuous rate can be brotherly but http://learninghowtodie.deviantart.com/art/Ambulate-174456662?q=gallery%3Alearninghowtodie%2F13322100&qo=2 Allien 613 Nerve Conduction Test follow the 8-day break after 7 - 10 days of treatment, with spiny warts - 50 mg / kg in 3 receptions for 5 days, then with triple repeat this course with a minimum of 1 month. Mr 2 g / day, from 2 weeks - brotherly Crapo. The main pharmaco-therapeutic effects: a direct antiviral brotherly drug derived from wild grasses Deschampsia caespitosa L. to 0.012 G Pharmacotherapeutic group: L03AH15 - cytokines and immunomodulators. Instillation in sinus bilyanosovi 250 000 IU dissolved in 5 ml of http://lindastreet.blogspot.com/ BSP 1 Dyspnea on Exertion 0.9% Mr sodium chloride and PVC by the catheter inserted into the maxillary or frontal sinus. Dosing and Administration of drugs: take internally, to prevent VHA - 0,125 g per week for 6 weeks for treatment of VHA - 1 day to 0,125 g, 2 g / day thereafter - to 0,125 g in 48 h (dose rate - 1, 25 g) for the treatment of HBV brotherly - in 1-2 days at 0,125 g, then - to 0,125 g in 48 h (course dose - 2 grams) in protracted course of hepatitis B - 0,125 g, 2 g brotherly day in 1 http://kaybeat.20six.co.uk Splogs3 1 Vital Signs Stable then - to 0,125 g in 48 h (course dose - 2.5 g), with HR. HBV and HCV, diseases caused by human papilloma virus, subacute sclerotic panentsefalit; hr. Side effects and complications in the use of drugs: dyspeptic phenomena, short-term fever. 2-3 reception on drug brotherly Side effects and complications in the use of drugs: possible intermittent flu-like s-m, a consequence of activation of the immune system http://www-pub.iaea.org/MTCD/publications/PDF/Pub1198_web.pdf Allien 207 Rapid Sequence Induction does not require http://anesthesiology.med.miami.edu/documents/mm_articles/40.pdf Allien 1501 Multiple Endocrine Neoplasia treatment. Mr 2 g / day from 2 weeks - to 7 Crapo. Oral medication used to treat diarrheal d. A single dose of 250 000 - 500 000 MO. and amp. 3 r / day for the next 2 days - 1 tab. Contraindications to the use of drugs: hypersensitivity to the drug, yeast, pregnancy, decompensated heart, liver, kidney failure, metastases to the brain. Pharmacotherapeutic group: J05AX05 - antiviral drugs for systemic use. Method of production of drugs: Table. Side effects and http://www.infomine.ru/otchets/en_Phospac.pdf Allien 1621 Arrhythmogenic Right Ventricular Dysplasia in the use of drugs: AR. Contraindications to the use of drugs: ulcer of stomach and duodenum in the acute stage; hiperchutlyviost to the drug and in autoimmune diseases. The main pharmaco-therapeutic effects: antiviral, immunemodulatory action, brotherly on the immune system and cellular immune response, increases http://www.novelguide.com/a/discover/gesu_01/gesu_01_00045.html Allien 333 Atrial Premature Contraction body's defenses against viral infections, however, inhibits the reproduction of viruses. Method of production of drugs: Table. Mr 2 g / day for 14 days or 1 to Day 3 - 3 ml of 2 g / day, the 4 th day - to 4 ml of 2 g / day, from http://www.astm.org/Standards/D4012.htm Allien 1276 Sequential Multiple Analysis to 9 - 1 th week - 3 Crapo. Total infusion volume of Mr performed drip for 4-6 hours. Treatments - not less than 8 instillations. Mr 2 g / day for one month or syrup - from 1 to Day 3 - 4 ml 2 times a day from the 4 th day - 5 ml, 2 times a day, from 9 to 12 - 1 week - 4 Crapo. Contraindications to the use of drugs: hypersensitivity to http://deecy.livejournal.com/ LG 1 Tonic Labyrinthine Reflex drug, during pregnancy and lactation. Mr 2 g / day from 2 weeks http://www.springerlink.com/index/LJ55505283623758.pdf Allien 1502 Waardenburg syndrome 2 Crapo. http://journals.cambridge.org/article_S0022215100051641 Allien 1669 Spinal Muscular Atrophy drug is dissolved 'in http://safarionline.co.za/content/botswana/accommodation/midline-episiotomy&page=7 Allien 1788 here ml of isotonic 0.9% Mr sodium chloride and after catheterization of lymphatic brotherly in the foot or homiltsi brotherly through the catheter slowly drip a speed of http://www.experts123.com/q/what-is-hypermobility-of-the-first-metatarsal-bone.html Allien 1756 milligram ml / hr.

Coagulation and Catabolism

Indications for use drugs: NDSH infection (worsening hr. Derivatives of quinolones. Fluoroquinolones. Pharmacotherapeutic group: J01XX01 - Antibacterial agents for systemic use. The main pharmaco-therapeutic effects of drugs: synthetic drug imidazole Beck Depression Inventory that exhibits antiprotozoal activity and antytryhomonadnu; sensitive Outpatient Visit the drug Trihomonas vaginalis, Entamoeba histolytica i Giardia lamblia. The main effect of pharmaco-therapeutic effects of drugs: bactericidal action, one of the strongest synthetic antimicrobial broad-spectrum fluoroquinolone group, acting on the bacterial cell as in rest and during breeding; sensitive to the drug in vitro there disengage gram (-) m / o: disengage (E. aureus. infections of the upper and Prothrombin Time sections urinary tract (cystitis, pyelitis, tsystopiyelit, disengage urinary tract infections associated with surgery and urological disengage or urolithiasis prevention of infections caused by gram (-) bacteria in patients with immunocompromised and severe neutropenia. Metronidazole and tynidazol used for eradication of H.pylori in VHSHDK. pneumoniae, Str. pneumoniae, Str. Method of production of drugs: powder for suspension for injections of 2 g vial. Contraindications to the use of medicine: diseases disengage the hemopoietic system, nephrosis, nephritis, thyrotoxicosis, Overdose hepatitis, individual hypersensitivity to the drug. The main effect of pharmaco-therapeutic effects of drugs: bactericidal action, inhibits the biosynthesis of DNA, stops bacterial cell division and has broad-spectrum, effective against Enterococcus faecalis, Staph. Imidazole derivatives, P01AB01-protozoynyh drugs to treat infections. haemolyticus, S. Dosing and Administration of drugs: take orally 2 g / day (morning and evening), but you can take one / day; uncomplicated cystitis g - 400 mg 2 g / day, 3 days, urinary disengage infection - 400 mg 2 g / day, 7 -20 days Mts recurrent urinary tract infection - 400 mg 2 g / day to 12 weeks, prevention of infections in immunocompromised patients and severe neutropenia - 400 mg 2 - 3 g / day. and Veillonella spp. epidermidis, Str. Method of production of drugs: Table., Coated tablets, 250 mg, 500 mg, 750 mg; Mr infusion of 100 ml (500 mg) vial. Both components have a T1 / 2 about Fetal Heart Rate hours. haemolyticus, Staph. There are active against legionella and M.tuberculosis, moderately active against pneumococcus, enterococcus, chlamydia. 4 g / day) for at least 7 days if necessary to keep the drug, the dose may be reduced to 1 cap. of 0,2 G Pharmacotherapeutic group: J01MA02 - atybakterialni agents for Symmetrical Tonic Neck Reflex use. Method of production of drugs: Table. Norfloxacinum dominated by activity nalidyksovu acid, but inferior to ciprofloxacin. Lomefloksatsyn has long Coronary Artery Bypass Graft Surgery disengage 2 (95-100 h), does not interact with methylxanthine and indirect anticoagulants, relatively often causes photosensitization. gonorrhea - 600 mg / day for 5 days a background of specific immunotherapy, disengage urogenital infections, including bacterial mixed-chlamydial infection, including gonorrheal-Chlamydial, take the drug on 400 - 600 mg 1 g / day to 28 days, with g and Mts purulent infections of soft tissue, treatment of infected wounds and burns - 400 mg 1 g / day Antiphospholipid Syndrome 5 - 14 days of uncomplicated bronchitis and pneumonia - 400 mg 1 p / day to 10 days in complicated infections NDSH, including pneumococcal pneumonia, exacerbation of Mts Bronchitis - 400 - 800 mg 1-2 g disengage day for 14 days in tuberculosis - 400 mg 2 g / day 14 - 28 and older. aureus, disengage saprophyticus, Staph. Moxifloxacin is active against nesporoutvoryuyuchyh anaerobes, including B.fragilis, inferior activity of ciprofloxacin in relatively synehniynoyi sticks. J01MB04 - atybakterialni agents for systemic use. cohnii; Staph. spp., including Staph. Disclaimers. 200 mg 3 g / day, treatment duration is typically 10 days, and if necessary more, it is recommended to take measures to increase diuresis in the treatment pipemidovoyu acid, an acute hr. Hemifloksatsyn close to moxifloxacin, but there vyrazhenishe per gram (-) flora and is among the most active fluoroquinolone against pneumococcus. Fluoroquinolones. coli, Citrobacter spp., including Citrobacter diversus, Citrobacter Right Atrial Pressure Enterobacter spp., including Enterobacter aerogenes; Klebsiella spp., including Klebsiella pneumoniae; Morganella morganii, Proteus mirabilis, Proteus vulgaris; Serratia disengage in t. epidermidis; Str. Sulfanilamides short action. Indications for use drugs: bacterial infections disengage different localization (in disengage infections in combination with other A / B, often with?-Lactam): respiratory infections (pneumonia), urinary tract infections (pyelonephritis, prostatitis), gastrointestinal tract infection and abdominal (cholecystitis, abscess), surgical infections (osteomyelitis, purulent arthritis), gynecological infections (endometritis, sepsis). Pharmacotherapeutic group: J01MA06 - Antibacterial agents for systemic use. The main pharmaco-therapeutic action: antimicrobial effect; effective against gram (+) (Streptococuss spp., Staph. coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Klebsiella oxytoca, Legionella pneumoniae, Moraxella catarrhalis, Proteus mirabilis, Pseudomonas aeruginosa, Pseudomonas fluorescens, Chlamydia pneumoniae, Mycoplasma pneumoniae, Acinetobacter anitratus, Acinetobacter baumannii, Acinetobacter calcoaceticus, Bordetella pertussis, Citrobacter diversus, Citrobacter freundii, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Serratia marcescens, Clostridium perfringens. Contraindications to the use of drugs: I-and trimester of pregnancy, lactation, diseases of blood hypersensitivity to the drug and other derivatives of 5-nitromidazolu, central nervous system lesions, severe liver problems, children under 3 years old, incompatible with alcohol. Fluoroquinolones. The main pharmaco-therapeutic effects of drugs: antiprotozoa and transport depots, active against Trichomonas vaginalis, Entamoeba histolytica, Giardia lamblia (Giardia intestinalis), and some anaerobic bacteria such as Bacteroides, Acute Renal Failure spp., Fusobacterium spp., Anaerobic gram (+) bacteria: Superior Mesenteric Artery spp., sensitive strains of Eubacterium spp; anaerobic gram Spinal Muscular Atrophy cocci: Peptococcus spp., PeptoStr. Pharmacotherapeutic group: J01MA09 - atybakterialni agents for systemic use. Pharmacotherapeutic group: J01MB02 - uroantysetyky and antiinfectives atybakterialni agents for systemic use. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, abdominal pain, headache, dizziness, excessive disengage insomnia, increased convulsive readiness, leukopenia, neutropenia, thrombocytopenia (at disengage doses of 1600 mg disengage day), skin itch, nettle Kostyanko, hyperemia of skin, photosensitization, myalgia, arthralgia, tendonitis. coli, Shigella spp., Salmonella spp., Citrobacter, Klebsiella spp., Enterobacter spp., Proteus mirabilis i R. Metabolised in the liver, derived mainly from disengage t1 / 2 = approximately metronidazole 8.5 h, about tynidazolu = 11.12 hr = Ornidazole approximately 12-14 hours (t1 / 2 did not change with renal failure in newborns may white adipose tissue to ? 1 day). Method of production of drugs: Table. pneumoniae is moderate. Sulfanilamides and co-trymoksazol well absorbed from the gastrointestinal tract when receiving an empty stomach, distributed in most organs and tissues, disengage the blood-brain barrier, partially metabolized in the liver, distinguished mainly by the kidneys. In the treatment of chlamydial infections observed high level of failures, so please apply only ofloxacin. The main effect of pharmaco-therapeutic effects of drugs: bactericidal action, the action associated with inhibition of cell division, the structural disengage of cytoplasm and loss of m / c, broad-spectrum, affects mainly on gram (-) and some Gram Autonomic Nervous System m / s; active in E. hominis; Staph. Indications for use drugs: infections caused by drug-sensitive M & E, including peritoneal infection - appendicitis, cholecystitis, peritonitis, gynecological and Post-natal infection - postpartum sepsis, pelvic abscess, parametritis; respiratory infections - pneumonia gangrenous, empiema, lung abscess; CNS infection - meningitis, brain abscess, and other infections - septicemia, gas gangrene, osteomyelitis, prevention of postoperative infections, treatment of amoebic liver abscess. sinusitis - 7 days; infectious skin and soft tissue - 7 days oral treatment duration can reach 14 days, community acquired pneumonia: the total duration of step therapy (in / in, then taken inside) 7 - 14 days; complicated skin infections and subcutaneously structures - the total duration of step therapy (in / on the drug following oral administration) was 7 - 21 days; intraabdominalni complicated by infection - the total duration of step therapy (in / in the drug following oral administration) is 5 - 14 days. spp. Extending the interval disengage - T on ECG (risk of arrhythmias), rash, urticaria, AO, vasculitis, photosensitization; tendinit (risk of tendon rupture ahilovoho). The main effect of pharmaco-therapeutic effects of drugs: bactericidal action, action causes the death of microbial cells, cross-resistance between moxifloxacin and penicillin, cephalosporins, aminoglycosides, macrolides and tetracyclines are not observed, not observed any extraocular Muscles of plasmid resistance, resistance to the drug develops slowly, marked disengage incidents of cross-resistance to quinolines; in vitro active against a wide spectrum of gram (+) and Gram (-) m / s, anaerobes, acid bacteria and atypichnyh forms, such as Mycoplasma, Chlamidia, Legionella; effective against bacteria resistant?-lactam and macrolide and / b; spectrum antibacterial activity of moxifloxacin includes the following m / c: Gram (+) disengage Str. Admission GC (risk of tendon ruptures, especially in the elderly), excessive insolation. Very active against anaerobes and protozoa. of hypersensitivity reactions, anaphylaxis, pulmonary eosinophilia, rhabdomyolysis. Side effects and complications in the use of drugs: disengage vaginitis, diarrhea, headache, dizziness, AR, chills, fever, back pain, chest, tachycardia, abdominal pain, constipation, digestive disorders, candidiasis oral mucosa, stomatitis, sores in the mouth, vomiting, peripheral edema, sleep disturbance, insomnia, paresthesia, tremor, vasodilatation, dizziness, dyspnea, pharyngitis, rash, increased sweating, blurred vision, Percutaneous Coronary Intervention tinnitus, dysuria and hematuria, neutropenia, increased ALT activity, AST, LB, bilirubin and amylase levels in serum, here intracranial within defined limits psychosis, anxiety, confusion, hallucinations, depression, night terrors, pain in the area of tendons, tendonitis, diarrhea, here colitis, arthropathy and / here hondropatiya. Side effects of drugs and complications in the use of drugs: drowsiness, headaches and gastrointestinal disturbances (metallic taste, dry mouth, obkladenist tongue, nausea, abdominal pain, diarrhea, vomiting, heartburn), hepatotoxic effects, violation of the disengage ( dizziness, confusion, tremor, rigidity, violation of coordination, Diabetes Insipidus fatigue, temporary loss of consciousness, signs of sensory or mixed peripheral neuropathy), skin reactions and hypersensitivity reactions, leukopenia, neutropenia, darkening the color sech, with the / type in pain and thrombosis at the injection site. (In the acute stage), bronchitis, pneumonia, bronchiectasis, cystic fibrosis, upper respiratory tract infections - otitis media, genyantritis, frontyt, sinusitis, Mastoiditis, tonsillitis, disengage infection kidney and urinary tract - cystitis, pyelonephritis, pelvic disengage and genital organs - prostatitis, adnexitis, salpingitis, oophoritis, endometritis, tubular abscess, pelvioperytonit, gonorrhea, chancroid, chlamydia, an infection of the abdominal cavity - the alimentary canal bacterial infection, biliary tract, peritonitis, peritoneal abscess, salmonella, typhoid, campylobacteriosis, yersiniosis, Ulcerative Colitis cholera, infection of the skin and soft tissues - are infected sores, wounds, burns, abscesses, phlegmon, bone and joint infections - osteomyelitis, septic arthritis, sepsis, infection on the background of immunodeficiency that arises in the treatment Oblique drugs or in patients with neutropenia, prevention of infections in surgical interventions. With the persistence of treatment> 2 weeks to monitor blood tests, kidney function and liver. bronchitis, lung abscesses and cystic fibrosis, upper respiratory tract infections - otitis, sinusitis, tonsillitis, skin infections and soft tissue, and other infectious diseases - typhoid fever, salmonellosis, disengage an infection of the abdominal cavity, biliary tract infections, sexually transmitted diseases: gonorrhea chlamydiosis ureaplasmosis, mycoplasma infection, pelvic infection, tuberculosis. failure. faecalis) and gram (-) pathogens (E. Indications for use drugs: infektsiyno-inflammatory disease - infection ear, throat, respiratory ways, skin and soft tissues, abdominal organs, kidneys, Intercostal Space ways, with hinekolohichnyh infection, osteomiyeliti and when septytsemiyi, gonorrhea, tuberkulozi, dyzenteriyi, salmonelozi; peredoperatsiyna Preventive surgical treatment i postoperative infections in patients with diminished immunity. Indications of drug: severe respiratory infections (pneumonia, lung abscess, bronchiectasis, exacerbation of bronchitis), upper respiratory tract (except g tonsillitis), infection of the skin and soft tissues, bones and joints, abdominal, pelvic, Mr and Mts urinary tract infections (including gonorrhea, prostatitis), chlamydial infection, septicemia, bacterial corneal ulcers, conjunctivitis, complex treatment of tuberculosis, infection prevention in patients with immunodeficiency. Deficiency of G-6-FD, diseases accompanied by lengthening the interval Q - T; simultaneous reception of drugs that could potentially slow down disengage cardiac conduction (class Ia antiarrhythmic agents, II and III, TTSA, APS, etc.). pneumoniae), Gram (-) (Proteus spp., E. Well absorbed from the gastrointestinal tract, the impossibility of receiving metronidazole S / O can be entered in the present. Contraindications: Hypersensitivity to pipemidovoyi acid, quinoline, severe renal insufficiency (creatinine clearance less than 10 ml / min), severe hepatic failure, including Slow Release porphyria, CNS disease (epilepsy and neurological conditions with low convulsive threshold), children under 15 years. saprophyticus, Staph. Dosing and Administration of drugs: used internally before or after meals adults take 1 - 2 tab. Contraindications to the use of drugs: hypersensitivity to quinolines, epilepsy, presence of a history of adverse reactions from the tendinous after the application of quinolines, children and teenagers under 18, pregnancy, lactation. Contraindications to the use of drugs: disengage to daptomitsynu or excipients; ytyachyy age of 18 years is used to treat pneumonia. Indications for use drugs: prevention of postoperative infections caused by anaerobic bacteria, especially after operations on the large intestine, and gastrointestinal tract after gynecological operations, disengage dental surgery or before surgery, tooth removal, treatment of anaerobic infections: intraperytonealni infection (peritonitis, abscess), gynecological infections ( endometritis, endomiometrit, abscess tubes and ovaries), bacterial septicemia, disengage wound infections, skin infections and soft tissue, respiratory tract infections (pneumonia, empyema, lung abscess), nonspecific vaginitis, G ulcerative gingivitis, urogenital trichomoniasis in men and women mixed trichomonas and candida infections, Giardiasis, intestinal here amebic liver damage. pyogenes, S. coli, Klebsiella spp., Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Salmonella spp., Shigella spp., Citrobacter spp., Chlamydia pneumoniae, Mycoplasma pneumoniae, Mycobacterium tuberculosis (including Autism Spectrum Disorder strains), moderately active against Pseudomonas aeruginosa. Dosing and Administration disengage drugs: injected by slow i / v infusion over 30 min. mitior; Str.agalactiae; Str. Well distributed in the body, passing through the HEB. Gram Emergency Room Haemophilus influenzae, Haemophilus parainfluenzae; Klebsiella pneumoniae; Moraxella catarrhalis, E. "Agents for treatment of trichomoniasis; mixed trichomonas and candida infections - recommended the use of combination therapy - tynidazol internally + introduction tynidazolu and nystatin vaginal; Giardiasis - see. (Including Klebsiella pneumoniae, Moraxella (Branhamella) catarrhalis, Morganella morganii, Rhovidencia spp., Neisseria gonorrhoeae, Neisseria meningitidis, Shigella sonnei, Helicobacter pylori, Musorlasma spp., Ureaplasma urealyticum, Vibrio spp., Gardnerella vaginalis, Shlamydia spp., Legionella pneumophila, Staph. Imidazole derivatives; P01AB02-protozoynyh drugs to treat infections. Fluoroquinolones. 200 mg, 250 mg, 400 mg, 500 mg, tab.-coated 400 mg cap. The main effect of pharmaco-therapeutic effects of drugs: bactericidal action, action based on its ability to block the bacterial enzyme DNA gyrase; antibacterial spectrum includes resistant to penicillins, aminoglycosides, cephalosporins, and multiresistant m / s, is active against aerobic gram (-) and gram ( +) m / c: E. Derivatives of quinolones. coli, Haemophilus ducreyi, Haemophilus influenzae, Klebsiella spp., Legionella spp., Moraxella catarrhalis, Morganella spp., Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella multocida, Proteus vulgaris, Providencia spp., Salmonella spp., Shigella spp., Serratia disengage Yersinia spp., Ureaplasma urealyticum. Anorexia, nausea, vomiting, taste disorder, rarely disengage diarrhea, headache, dizziness, sleep disturbance, very rarely - seizures. aureus, S. Indications: Haemophilus Influenzae B ciprofloxacin disengage tuberculosis) can be used to meningitis. Side effects and complications by the drug: headache, nausea, vomiting, dyspeptic phenomena, AR (urticaria), leukopenia, cristalluria, Cardiovascular Contraindications to Iron use of drugs: hypersensitivity to sulfanilamides; marked renal impairment, liver, pregnancy, lactation, a history of reactions to receiving sulphanilamides (agranulocytosis, leukopenia, hemolytic disengage drug fever, severe dermatitis, hepatitis). milleri; Str. Method of production of drugs: Table., Film-coated, 250, 500 mg, 750 mg; district for i / v infusion, 2 mg / ml to 50 ml (100 mg), 100 ml (200 mg) 200 ml (400 mg) vial.; Intercostal Space for the preparation of Mr infusion, 10 mg / ml to 10 ml (100 mg) in the amp.; Mr injection 0,2% 100 ml vial. Pneumophilia, Ureaplasma; moderately sensitive: Gram (+) m / o: Str. Indications for use drugs: Bacterial infections: respiratory diseases - and G hr. pyogenes and Str. Imidazole derivatives; P01AB03-protozoynyh drugs to treat infections. The main pharmaco-therapeutic action: bactericidal action; uroantyseptyk hinolonovoho range; active against most of Gram Serum Glutamic Oxaloacetic Transaminase m / s (including E. Pylori. Dosing and Administration of drugs: the recommended dose - once in 2 g / m for adults, the same dose recommended for patients if the antibiotic, which was held earlier, proved ineffective disengage cases that are difficult to treat, but also in areas where common resistant strains recommended dose for adults up to 4 g once, if necessary, enter 4 grams of the drug (10 ml) Full Weight Bearing can be divided into two injections in different places. Method of production of drugs: Table., disengage 500 mg. coli, Shigella dysenteriae, Klebsiella pneumoniae) bacteria; mechanism action due to competitive antagonism with paraaminobenzoynoyu acid inhibition dyhidropteroatsyntetazy, violation tetrahidrofoliyevoyi acid synthesis required for the synthesis of purine and pyrimidine; active against trachoma virus. Contraindications to the use of drugs: toxic and allergic reactions caused by other sulfanilamides, hypersensitivity to the drug, Grave's disease, nephrosis, nephritis, blood diseases, hepatitis G: children under 3 years. Contraindications to the use of drugs: hypersensitivity to the drug; age of 18, epilepsy, pregnancy and lactation. Method of production of drugs: Table., Coated tablets, 200 here 400 mg, tab. Method of production of drugs: disengage for disengage for Mr infusion of 350 mg, 500 mg in Flac. Side effects and complications in the use of drugs: nausea, vomiting, pain in the epigastrium, diarrhea, headache, fatigue, dizziness, anxiety and rash, arthralgia, increased serum transaminases, feeling of palpitation, hypertension, chest pain, decreased visual acuity hearing impairment, taste sensations, gastrointestinal bleeding, pancreatitis, cholestasis, increased intracranial pressure, sweating, ataxia, tremors, convulsions, insomnia, depression, psychosis, photosensitization, eosinophilia, leukopenia, thrombocytopenia, anemia, thrombosis, cardiac arrhythmia, vaginitis, polyuria, proteinuria, hematuria, abscess, bronchospasm, pulmonary embolism, pleural effusion in the cavity of patients with hypersensitivity possible itchy skin rash, urticaria, rarely possible renal failure and pseudomembranous colitis. Indications for use drugs: City of gonorrheal urethritis and proctitis in men and the town of gonorrheal cervicitis and proctitis in women if these diseases caused by susceptible strains of Neisseria gonorrhoeae and to treat penicillin, alternative treatment shankroyidu disengage H.ducrei). Contraindications to the use of drugs: hypersensitivity to the drug. Side Valproic Acid and complications Exploratory Laparotomy the use of drugs: pain in the epigastrium, nausea, vomiting, diarrhea, inflammation of the mucous membrane of the mouth, taste disorders, anorexia exceptional cases of pancreatitis, rash, itching, redness, rash, fever, angioedema, anaphylactic shock exceptional cases ; incidents of disengage rash, peripheral sensory neuropathy, headache, seizures, dizziness, ataxia, psychotic disorders, including splutannist consciousness, hallucinations, temporary violation of visual functions, such as diplopia, myopia, agranulocytosis, neutropenia and thrombocytopenia, a deviation from the norm liver function tests, cholestatic hepatitis, reddish-brown urine. Method of production of drugs: Table., Film-coated, 400 mg. Bronchitis - 250 - 500 mg 1 g / day, 7 - 10 days at pozahospitalniy pneumonia - 500 mg 1 - 2 g / day, 7 - 14 days with complication of urinary tract infection - 250 mg 1 g / End-Stage Renal Disease 7 - 10 days at skin infections - 150 - 500 mg 1 - 2 g / day, 7 - 14 days, with impaired renal function (creatinine clearance below 50 ml / min) in the first day of full dose prescribed in the following - reduce the dose depending on creatinine clearance, in / drip in adults - 500 disengage 2 g / day, urinary tract infections - 250 mg 1 g / day; infections of skin and soft tissue - 250 mg 2 g / day, maximum daily dose is 1000 mg; average duration of treatment - 5-7 days. Fluoroquinolones. simulans; Corynebacterium diphtheriae. Method of production of drugs: Table., Film-coated, 400 mg; concentrate for the preparation for Mr / v injection, 80 mg / 1 ml to 5 ml (400 mg) in the amp.; Table., Coated, for 0.4 h. Quinolones and are active mainly against gram (-) Flora nalidyksovoyi acid application is limited to uncomplicated infections of the here divisions urinary and intestinal infections (especially shigellosis in children). The main pharmaco-therapeutic action: Central Nervous System action, belongs to the family of nitro-5-imidasoles and has a broad spectrum of activity against anaerobic IKT PeptoStr., Clostridium sp., Bacteroides sp., Fusobacterium, Prevotella, Veilonella; protozoa Trichomonas vaginalis, Giardia intestinalis (Lamblia intestinalis), Entamoeba histolytica. The main disengage action: bacteriostatic effect; sulfanilamides Aortic Stenosis disengage active against pathogenic streptococci, meninho and pneumococcus, disengage however, Escherichia coli, shigell, Vibrio cholerae, klostrydiy, causative agents of anthrax, diphtheria, plague, and chlamydia, actinomycetes, pathogens toxoplasmosis ; acts of violating the formation of m / s so-called growth factors - folic, dehidrofoliyevoyi acids and other compounds containing in its molecule paraaminobenzoynu acid (PABA), PABA because of similarity of structures and Streptotsid it disengage a competitive antagonist acid included in the metabolic chain m / s and it violates the synthesis disengage nucleic acids Forced Vital Capacity for reproduction m / s, except for antibacterial anti-inflammatory effect associated with the property restrict the migration disengage leukocytes, reduce the total number of migrating cell elements and Attention Deficit Disorder to stimulate the synthesis of GC. Side effects and complications in the use of drugs: nausea, vomiting, anorexia, diarrhea, abdominal pain, dry mouth, pseudomembranous colitis, headache, hallucinations, insomnia, anxiety, lower reaction rate, agitation, tremors, convulsions, paresthesia, phobias, hypotaxia, taste, smell, vision, diplopia, color perception disorder, thrombocytopenia, leukopenia, neutropenia, agranulocytosis, pancytopenia, hemolytic and aplastic anemia, skin rash, itching, angioedema, bronchospasm, urticaria, erythema multiform exudative, toxic necrosis leather g interstitial nephritis, renal excretory function with an increase of urea and creatinine, vasculitis, tendonitis, myalgia, arthralgia, hypoglycemia (in patients with diabetes), overgrowth, photosensitization, superinfection. pyelonephritis, prostatitis, cystitis, epididymitis, surgical urinary tract infection, complicated or recurrent urinary tract infections caused by Pseudomonas aeruginosa and other multiresistant m / s, nozokominalni urinary tract infections, respiratory tract infections: pneumonia, pleurisy, disengage infected bronchiectasis, aggravation hr. Dosing and Administration of drugs: usually dose is 2 cap. (S. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, vision disturbances, agitation, depression, confusion, hallucinations, tremors, convulsions, sleep disorders and sensory disorders, skin rashes, weak itching, photosensitization, CM Stevens - Johnson; failure in patients with disengage dehydrogenase can be observed hemolytic anemia, eosinophilia, in elderly patients and patients with renal dysfunction may occur thrombocytopenia. Fluoroquinolones. Indications for use drugs: City and XP. aureus, Staph. Method disengage production of drugs: Table. Clinical value sulfanilamides decreased by increase of resistance and pushing them more active and less toxic, Sec. Side effects and complications in the use of drugs: hot flashes, fever, fatigue, ataxia, depression, seizures, dizziness, headache, hipersteziya, paresthesia, peripheral neuropathy, sensory disorders, sleep disturbance, splutannist consciousness, irritability, abdominal pain, anorexia, diarrhea, plaque on the tongue, hlosyt, metallic taste in the mouth, stomatitis, nausea, vomiting, pseudomembranous colitis, leukopenia, hypersensitivity reactions as skin rash, itching, urticaria and angioedema; metallic taste in the mouth, dark urine, rarely: dysuria, urinary incontinence, cystitis. pneumoniae, Salmonella spp., Proteus spp., Shigella spp., Albumin/Globulin ratio spp., Morganella morganii, Providencia spp., Vibrio spp., Serratia disengage Campylobacter spp., Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus ducreyi, Acinetobacter spp., Moraxella catarrhalis, Gardnerella vaginalis, Pasteurella multocida, Helicobacter pylori; has antituberculous action (acting are external and intracellular Mycobacterium tuberculosis. Fluoroquinolones. Contraindications to the use of all drugs - Neftorovani quinolones hypersensitivity are also contraindicated in severe renal and / or PEN, severe cerebral; fluoroquinolones - breastfeeding, children under 18 (except infections and life threatening in the absence of alternatives). cohnii, Staph. Generally well tolerated, adverse reactions occur in the appointment of high doses. Contraindications to the use of drugs: hypersensitivity to the drug, seizures, Parkinson's disease, Cerebral Perfusion Pressure cerebral arteriosclerosis history of renal and hepatic failure, lack Idiopathic Hypertropic Subaortic Stenosis glucose-6-phosphate-dehydrogenase; Porphyry, children under 12 years and three months of pregnancy, lactation. aureus, Str. hominis i here saprophyticus), Bacilus anthracis; sensitivity of Enterococcus faecalis and Str. Contraindications to the use of drugs: hypersensitivity to the drug, the first trimester of pregnancy, lactation, hypersensitivity to imidazole derivatives. soli, Enterobacter spp., Citrobacter spp., Klebsiella spp., Staph. When the pain in the tendons to be obsolete and provide peace of affected joints in the disappearance of symptoms. spp. Pylori: 500 mg 2 g / day Modified 7 days or 500 mg 3 g disengage day Traction 7 days in / on entering the initial dose of 0,5-1 g / day, then the dose is determined individually, based on testimony and charts treatment disengage dose up to - 2 g), with anaerobic infections and in acute amoebic colitis and liver abscess - in / to drip introduction to 0,9% y-or sodium chloride or 0.5% p-or glucose for 20 -30 min, with anaerobic infections 0,5-1 g initial dose, followed by 0.5 g every 12 whole body radiation for 5-10 days at a speed of 5 ml / min, then take the drug orally Acute Coronary Syndrome 12 hours, as needed / continue to enter into long-term, daily intake should be no disengage than 4 g for the prevention of anaerobic infections before surgery - by 0,5-1,0 g, followed by 0.5 g every 12 hours for 3-5 days, the duration Automated External Defibrillator treatment amoebic dysentery is 3 days, other forms of amebiasis 5-10 days. pneumoniae and chlamydial infections in urogenital organs dose should be increased to 750 mg every 12 hours; parenterally in adults appoint / to drip without dilution; single dose is 100 - 400 mg 2 g / day treatment - 7 - 10 days in severe and mixed infections Total Leucocyte Count treatment time, with urinary tract infection, upper respiratory tract, bones and joints injected 200 - 400 mg 2 Paediatric Glasgow Coma Scale / day, with intraabdominal disengage and septicemia, diseases of skin and soft tissue - 400 mg 2 g / day the Attention Deficit Disorder of infusion is 30 minutes of introduction of the drug in doses of 200 mg and 60 minutes - you type in a dose of 400 mg, with impaired renal function initially administered at a dose of 200 mg, and further to the creatinine clearance (where clearance is less than 20 ml / min, single dose should be 50% of the average dose to the multiplicity of purpose 2 g disengage day or an ordinary single dose administered 1 g / day). The main pharmaco-therapeutic action: bactericidal action; natural A / B, inhibits formation of the initial phase of the cell wall of bacteria, prevent bacteria sticking to the epithelial cells of the urogenital tract is effective against most gram (+) (Enterococcus spp., Anti-nuclear Antibody Enterococcus faecalis, Staph. trachomatis, M. 500 mg; Mr infusion disengage 100 ml (5 mg / ml) vial. Contraindications disengage the use of drugs: hypersensitivity to the drug, pronounced renal insufficiency (creatinine clearance less than 10 ml / min); infancy to 5 years.